Preimplantation Genetic Diagnosis Market to Reach US$28.8 mn by 2023

Preimplantation genetic diagnosis (PGD) is a reproductive technique that tests the chromosomes and genes of the embryos used in an intracytoplasmic sperm injection (ICSI), and can identify the presence of genetic anomalies, or aneuploidy. Demand for preimplantation genetic diagnosis is increasing among individuals who undergo IVF, as it reduces the chances of genetic disorders and disabilities rising in the child and improves the probability of live birth. The combination of preimplantation genetic diagnosis and IVF has curtailed the chances of passing on unsafe genetic materials to the embryo, thus refining the chances of successful pregnancy. Increasing incidence rate of genetic diseases is influencing patients to undergo PGD cycles for disease free offspring. Advanced techniques often lead to public unease, particularly when scientific and medical advances are moving ahead of public debate of the social and ethical concerns involved.

Download Complete Research Brochure PDF:

Growing awareness among patients about the advantages of using preimplantation genetic diagnosis is expected to boost the preimplantation genetic diagnosis market in Asia in the next few years. The rising occurrence of genetic disorders is expected to contribute to the growth of the market in the region in the near future. Moreover, factors such as untapped opportunities in the health care sector, rising medical tourism, and increasing health care awareness are expected to propel the growth of the PGD market in Asia. The preimplantation genetic diagnosis market is witnessing significant growth in Southern (Southeast) Asia due to decline in the fertility rates, resulting in more number of people opting for assisted reproductive technologies. Moreover, rapid increase in health care infrastructure, rise in disposable income, and increasing awareness among the people boost market growth.

The preimplantation genetic diagnosis (PGD) market in Asia has been divided based on test type, end-user, and geography. Based on test type, the market has been segmented into aneuploidy screening, chromosomal aberrations, gender selection, HLA typing, single gene disorder, and X-linked diseases. The aneuploidy screening segment accounted for the largest share of 35% of the PGD market in Asia in 2014. Aneuploidy is an abnormal condition, wherein the number of chromosomes is either less or more. Aneuploidy screening reduces the probability of transferring an embryo with chromosomal abnormality. Based on end-user, the market has been segmented into fertility clinics, health care facilities (including hospitals, diagnostic centers, and health care facilities), and academic institutes and research centers.

Usage of preimplantation genetic diagnosis for these applications has been increasing rapidly due to benefits associated with better pregnancy rate and birth of a healthy child. Aneuploidy screening using PGD has eased the method of detecting the risk of a syndrome caused due to variation in the number of chromosomes. Further research in this field has broadened the scope of applications of PGD in HLA typing, single gene disorder, and gender selection. Introduction of cost effective technologies, awareness and affordability of PGD tests are some of the recommendations provided for the market in Asia.

Major players in this market are Genesis Genetics (U.S.), Genea Limited (Australia), Illumina, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), Reprogenetics (U.S.), and Reproductive Genetics Innovations LLC (U.S.).

The PGD market Asia has been segmented as follows:

Asia Preimplantation Genetic Diagnosis (PGD) Market, by Test Type
PGD for Aneuploidy Screening
PGD for Chromosomal Aberrations
PGD for Gender Selection
PGD for HLA Typing
PGD for Single Gene Disorder
PGD for X-linked diseases

Read Full Report@